-
SARS-CoV-2 breakthrough infections in patients with immune-mediated inflammatory diseases during the omicron dominant period
Boekel, L., Besten, Y. R., Hooijberg, F., Wartena, R., Steenhuis, M., Vogelzang, E., Leeuw, M., Atiqi, S., Tas, S. W., Lems, W. F., van Ham, S. M., Eftimov, F., Stalman, E. W., Wieske, L., Kuijpers, T. W., Voskuyl, A. E., van Vollenhoven, R. F., Gerritsen, M., Krieckaert, C., Rispens, T., & 3 others, 1 Nov 2022, In: The Lancet Rheumatology. 4, 11, p. e747-e750Research output: Contribution to Journal › Comment / Letter to the editor › Academic
-
Breakthrough SARS-CoV-2 infections with the delta (B.1.617.2) variant in vaccinated patients with immune-mediated inflammatory diseases using immunosuppressants: a substudy of two prospective cohort studies
T2B! immunity against SARS-CoV-2 study group, 1 Jun 2022, In: The Lancet Rheumatology. 4, 6, p. e417-e429Research output: Contribution to Journal › Article › Academic › peer-review
-
COVID-19 vaccine acceptance over time in patients with immune-mediated inflammatory rheumatic diseases
Boekel, L., Hooijberg, F., Besten, Y. R., Vogelzang, E. H., Steenhuis, M., Leeuw, M., Atiqi, S., van Vollenhoven, R., Lems, W. F., Bos, W. H., Wijbrandts, C. A., Gerritsen, M., Krieckaert, C., Voskuyl, A. E., van der Horst-Bruinsma, I. E., Tas, S. W., Boers, M., Rispens, T., Nurmohamed, M. T. & Wolbink, G., 1 May 2022, In: The Lancet Rheumatology. 4, 5, p. e310-e313Research output: Contribution to Journal › Comment / Letter to the editor › Academic
- All publications
